000403 派林生物
按盤價 
14.350 -0.030 (-0.209%)
14.350 -0.030 (-0.209%) | 2025/09 - 九個月 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | 4.479 | 9.709 | 8.563 | 8.901 | 10.727 |
| 總資產報酬率 ROA (%) | 3.795 | 8.338 | 7.369 | 7.792 | 8.921 |
| 投入資產回報率 ROIC (%) | 4.036 | 8.974 | 7.999 | 8.489 | 9.918 | 邊際利潤分析 |
| 銷售毛利率 (%) | 46.318 | 49.132 | 51.481 | 52.127 | 46.072 |
| 營業利潤率 (%) | 26.664 | 33.161 | 29.853 | 27.583 | 23.351 |
| 息稅前利潤/營業總收入 (%) | 23.438 | 30.271 | 27.077 | 25.157 | 20.907 |
| 淨利潤/營業總收入 (%) | 22.093 | 28.065 | 26.258 | 24.434 | 19.858 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 101.735 | 98.379 | 100.163 | 98.707 | 105.739 |
| 價值變動淨收益/利潤總額(%) | 2.530 | 2.828 | -1.681 | 1.206 | 17.010 |
| 營業外收支淨額/利潤總額(%) | -6.027 | -3.229 | -1.029 | -0.460 | -0.528 | 償債能力分析 |
| 流動比率 (X) | 2.934 | 3.740 | 3.715 | 3.176 | 3.845 |
| 速動比率 (X) | 1.589 | 2.451 | 2.729 | 2.526 | 2.694 |
| 資產負債率 (%) | 16.251 | 14.371 | 14.004 | 14.046 | 10.724 |
| 帶息債務/全部投入資本 (%) | 10.887 | 7.190 | 5.987 | 4.511 | 1.270 |
| 股東權益/帶息債務 (%) | 811.195 | 1,279.664 | 1,551.423 | 2,083.639 | 7,632.613 |
| 股東權益/負債合計 (%) | 515.798 | 596.391 | 614.644 | 612.517 | 832.250 |
| 利息保障倍數 (X) | -13.707 | -16.344 | -10.952 | -10.939 | -9.005 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 106.427 | 82.369 | 109.718 | 102.622 | 74.207 |
| 存貨周轉天數 (天) | 460.671 | 285.599 | 244.231 | 213.018 | 199.877 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 09/01/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
